Objective: The epidemiological features of the cervical cancer (CC) incidence and its spatial and temporal assessment in Kazakhstan were studied. Methods: The retrospective study was done for the period 2009-2018. Descriptive and analytical methods of oncoepidemiology were used. Results: During the study period, 16,441 new cases of CC were registered. The average annual crude and age-standardized incidence rate were 18.6±0.5 and 17.7±0.4 cases per 100,000 population of female, respectively, and their trends tended to increase (Т up =+2.3%; R 2 =0.708 and Т up =+1.9%; R 2 =0.615, respectively). The analysis of ASIR showed unimodal growth with a peak at 50-54 years -45.3±1.1 cases per 100,000 population of female. Trends of ASIR decreased up to 30 years (T down =−1.8%; R 2 =0.111) and 35-59 years (T down =−0.9%; R 2 =0.103), in other age groups the trends increased, and were most pronounced in 40-44 (Т up =+4.1%; R 2 =0.878) and 65-69 years (Т up =+4.4%; R 2 =0.537). Trends in ASR of СС tended to grow in almost all regions, with higher levels in Mangystau (Т up =+4.1%; R 2 =0.482) and Aktobe (Т up =+6.3%; R 2 =0.846) regions. The cartograms of ASR per 100,000 population of female were allocated according to the following criteria: low -up to 16.3, averagefrom 16.3 to 19.2, high -above 19.2. The results of the spatial analysis showed the regions with a higher levels of CC incidence rate per 100,000 population of female: East Kazakhstan (19.8), Aktobe (20.0), Almaty (20.1), Kostanay region (20.9), Atyrau (21.7) regions and Almaty city (22.0). Conclusion: The study of trends of the cervical cancer incidence has the theoretical and practical value: monitoring and evaluation of screening programmes, which are implemented in the country, and conduction of secondary prevention of cervical pathology. Health authorities should consider the obtained results in the in the organization of anti-cancer activities.
<b>Introduction: </b>High incidence of thrombotic events has been reported in hospitalized patients with COVID-19. Less than 50% of pulmonary embolisms (PE) are associated with signs of deep vein thrombosis (DVT) of the lower extremities.<br /> <b>Objective:</b> To assess the risk factors of deep vein thrombosis (DVT) in intensive care patients with COVID-19 by comparing the clinical features of patients in groups with thrombosis, venous stasis and without deep vein thrombosis.<br /> <b>Material and methods:</b> A prospective cross-sectional study was conducted that included all consecutive adult patients with laboratory-confirmed COVID-19 admitted to the intensive care unit. We investigated chronic comorbid conditions in patients, including arterial hypertension, diabetes mellitus, obesity, chronic kidney failure (CRF), chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and cancer which may be a risk factor for thrombosis.<br /> <b>Results: </b>A total of 465 patients were included in the study. Comorbidities were present in 435 of 465 patients (93.55%). Doppler ultrasound (DUS) confirmed deep vein thrombosis in 60 patients (13.8%), which was associated with older age (71.12±13.98 vs. (79.57%), chronic heart failure - 196 (42.15%), obesity - 161 (34.62%), diabetes mellitus - 144 (30.97%), chronic renal failure (CRF) -58 (12.47%) and oncological diseases - 25 (5.38%). Hypertension (p=0.02), diabetes mellitus (p=0.041) and obesity (p=0.01) were significant risk factors for DVT. D-dimer was a statistically significant predictor of DVT formation (p<0.001), an increase in D-dimer per unit increased the risk of DVT by 14%.<br /> <b>Conclusion:</b> The study identified risk factors for deep vein thrombosis in intensive care patients with COVID-19. These include: age, high levels of D-dimer, and comorbidities such as hypertension, obesity, and diabetes mellitus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.